1086P - Diagnostic and prognostic impact of plasma osteopontin in nasopharyngeal carcinoma

Abstract

Background: We investigated the diagnostic and prognostic impact of plasma osteopontin (pOPN) concentrations in advanced nasopharyngeal carcinoma (NPC). Methods: Pre-treatment plasma samples from 138 patients with previously untreated and biopsy-proven NPC were collected. Plasma samples from another 70 healthy volunteer were served as control. OPN concentrations were measured by the enzyme-linked immunosorbent assay (ELISA). The patient characteristics were- age range 24-83 and median 48 years, male/female=97/41, WHO pathology type I/II/III=1/105/32, stage III/IV(M0)/IVC(M1) = 57/73/8. The treatment consisted of radiotherapy alone (2), concurrent chemoradiotherapy (28), and neoadjuvant chemotherapy plus radiotherapy (100) for M0 patients, and systemic chemotherapy with or without radiotherapy for M1 patients (8). Results: NPC patients (median 97.2 ng/mL; interquartile range 72.1-130.4) had significantly higher pOPN level than normal control (median 61.6 copies/ml; interquartile range 44.9-88.1), P<0.0001. The area under ROC curve is 0.754, P=0.0001. The median concentrations of stage III, IV(M0), and IV(M1) were 85.4, 104.2, and 217.7 ng/mL respectively (P=0.0002). We divided patients into two groups by pretreatment pOPN concentration and found that patients with higher pOPN (>100 ng/mL) correlated with some clinically poor prognostic factors, such as older age, male gender, advanced T-stage, and advanced overall stage. Pretreatment pOPN affected patients’ survival as well as rates of distant failure. The 5-year overall survival (56.6% vs. 81.4%, P=0.0036) and metastasis-free survival (66.3% vs. 81.2%, P=0.0726) were significantly lower in patients with pretreatment pOPN > 100 ng/mL than in those with pOPN < 100 ng/mL. Conclusions: Pretreatment pOPN levels can serve as a useful diagnostic and prognostic marker for advanced NPC. Legal entity responsible for the study: Taichung Veteran General Hospital Funding: Taichung Veteran General Hospital Disclosure: All authors have declared no conflicts of interest.